Silas Inman

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.

With the legalization of CBD products in 2018, many questions have emerged, not only on the laws governing these products, but on how to integrate CBD into community pharmacies.

Utilizing many of the skills learned in pharmacy school could help to personalize care and enhance medication delivery for patients, potentially leading to reductions in adverse drug events and health care costs,

The addition of the immunotherapy pembrolizumab (Keytruda) to standard presurgical chemotherapy improved pathological complete response (pCR) rates for patients with triple-negative breast cancer (TNBC).

A pharmacist and nurse led non-medical prescribing clinic that was focused on side effect management and survivorship support for patients with melanoma helped to improve common every-day pressure seen in a medical day unit and improved overall patient experience.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovations in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

Site-specific immune inflammation has been examined using intralesional injections of oncolytic viruses.

Data revealed at ASCO shows combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel reduced the risk of death by 22% compared with bevacizumab and chemotherapy.

Rituximab (Rituxan) and lenalidomide (Revlimid) showed similar efficacy to rituximab plus chemotherapy, according to findings presented at the 2018 ASCO Annual Meeting.

Following the approval of voretigene neparvovec, new treatments are on the horizon for retinitis pigmentosa.

Olaparib (Lynparza) double objective response rate compared with other breast cancer drugs.

Induction therapy shows the potential to achieve disease control in patients with locally advanced pancreatic cancer.

Cabometyx found to improve median overall survival by 2.2 months in patients with previously treated advanced hepatocellular carcinoma.